FDA loses veto power: foreign drug approvals now auto-approved in US

What it does

This bill creates a fast-track approval pathway for drugs, biologics, and medical devices that are already legally sold in certain wealthy countries (Canada, Australia, Japan, UK, etc.) or the UK. If a product meets basic safety criteria and addresses an unmet medical need in the US, the FDA must approve it within 30 days—unless Congress votes to block the approval. The bill treats foreign regulatory approval as sufficient evidence of safety and effectiveness, bypassing the FDA's standard clinical trial review.

Why we flagged it

The bill's operative mechanism is not patient access—it is manufacturer access. By deeming foreign approval sufficient and imposing a 30-day approval window with Congressional disapproval as the only override, the bill transfers approval authority from the FDA to foreign regulators and makes FDA rejection procedurally difficult. The framing as 'lifesaving treatments' masks a deregulatory carve-out for drug and device makers.

What the text implies

• The 30-day approval window and Congressional disapproval requirement create a procedural trap: FDA rejection is the default, but Congress must affirmatively vote to sustain it—a high bar. Most denials will likely take effect unless Congress acts, inverting normal regulatory burden.
• Foreign regulatory standards vary widely. Canada, Australia, and Japan have rigorous systems, but the bill's language ('one or more of the countries included in the list') means a product approved in a single permissive jurisdiction could qualify, creating a regulatory arbitrage incentive.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical manufacturers; medical device makers; biologics companies